The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12

AUTHORS

Devalingam Mahalingam, Sukeshi Patel, Gerard Nuovo, George Gill, Giovanni Selvaggi, Matt Coffey, Steffan T. Nawrocki

ABSTRACT

BACKGROUND: Activating mutations in RAS are present in the majority of pancreatic cancer cases and represent an ideal therapeutic target. Reolysin is a proprietary formulation of oncolytic reovirus that is currently being evaluated in multiple clinical trials due to its ability to selectively replicate in cells harboring an activated RAS pathway. Here we report for the first time the presence of reovirus replication and induction of endoplasmic reticular (ER) stress in a primary tumor specimen collected from a pancreatic cancer patient receiving intravenous Reolysin and gemcitabine. CASE PRESENTATION: We describe the case of a 54-year old patient diagnosed with pancreatic adenocarcinoma in February 2012. Analysis of a tumor biopsy revealed an activating KRAS mutation (G12D) and the patient was started on first-line treatment with Reolysin in combination with gemcitabine in March 2012. Stable disease was achieved with significant improvement in cancer-related pain. Following 25 cycles of treatment over 23 months, a second biopsy was collected and immunohistochemical analyses revealed the presence of reovirus replication and induction of the ER stress-related gene GRP78/BIP and the pro-apoptotic protein NOXA. Importantly, co-localization of reoviral protein and active caspase-3 was also observed in the biopsy specimen. CONCLUSION: This is the first report of reoviral protein detection in primary tumor biopsies taken from a pancreatic cancer patient receiving intravenous Reolysin therapy. The accumulation of reoviral protein was associated with ER stress induction and caspase-3 processing suggesting that Reolysin and gemcitabine treatment exhibited direct pro-apoptotic activity against the tumor. More... »

PAGES

513

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-015-1518-0

DOI

http://dx.doi.org/10.1186/s12885-015-1518-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018283520

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26156229


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endoplasmic Reticulum Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreas", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reoviridae", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahalingam", 
        "givenName": "Devalingam", 
        "id": "sg:person.01355241314.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355241314.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Sukeshi", 
        "id": "sg:person.0714313216.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714313216.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ohio State University", 
          "id": "https://www.grid.ac/institutes/grid.261331.4", 
          "name": [
            "Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nuovo", 
        "givenName": "Gerard", 
        "id": "sg:person.01024605131.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024605131.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncolytics Biotech (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459870.7", 
          "name": [
            "Oncolytics Biotech, Inc., Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gill", 
        "givenName": "George", 
        "id": "sg:person.01205716075.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205716075.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncolytics Biotech (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459870.7", 
          "name": [
            "Oncolytics Biotech, Inc., Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Selvaggi", 
        "givenName": "Giovanni", 
        "id": "sg:person.0770375641.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770375641.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncolytics Biotech (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459870.7", 
          "name": [
            "Oncolytics Biotech, Inc., Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coffey", 
        "givenName": "Matt", 
        "id": "sg:person.01014326765.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014326765.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nawrocki", 
        "givenName": "Steffan T.", 
        "id": "sg:person.01130425414.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130425414.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-012-9865-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010325857", 
          "https://doi.org/10.1007/s10637-012-9865-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2011.478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010906274", 
          "https://doi.org/10.1038/onc.2011.478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-015-0216-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015566041", 
          "https://doi.org/10.1007/s10637-015-0216-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-2181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021662085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/emboj/17.12.3351", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025374400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-1233", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031485445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2159", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032446761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cddis.2013.259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032595002", 
          "https://doi.org/10.1038/cddis.2013.259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1541-7786.mcr-12-0157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036233281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-12-368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037287741", 
          "https://doi.org/10.1186/1471-2407-12-368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.27918", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047508013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.34.8904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049252722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2012.95", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051526491", 
          "https://doi.org/10.1038/modpathol.2012.95"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(88)90571-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052805579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.282.5392.1332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062563200"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712590903002039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067587980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075250670", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.6.2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083106816"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12", 
    "datePublishedReg": "2015-12-01", 
    "description": "BACKGROUND: Activating mutations in RAS are present in the majority of pancreatic cancer cases and represent an ideal therapeutic target. Reolysin is a proprietary formulation of oncolytic reovirus that is currently being evaluated in multiple clinical trials due to its ability to selectively replicate in cells harboring an activated RAS pathway. Here we report for the first time the presence of reovirus replication and induction of endoplasmic reticular (ER) stress in a primary tumor specimen collected from a pancreatic cancer patient receiving intravenous Reolysin and gemcitabine.\nCASE PRESENTATION: We describe the case of a 54-year old patient diagnosed with pancreatic adenocarcinoma in February 2012. Analysis of a tumor biopsy revealed an activating KRAS mutation (G12D) and the patient was started on first-line treatment with Reolysin in combination with gemcitabine in March 2012. Stable disease was achieved with significant improvement in cancer-related pain. Following 25 cycles of treatment over 23 months, a second biopsy was collected and immunohistochemical analyses revealed the presence of reovirus replication and induction of the ER stress-related gene GRP78/BIP and the pro-apoptotic protein NOXA. Importantly, co-localization of reoviral protein and active caspase-3 was also observed in the biopsy specimen.\nCONCLUSION: This is the first report of reoviral protein detection in primary tumor biopsies taken from a pancreatic cancer patient receiving intravenous Reolysin therapy. The accumulation of reoviral protein was associated with ER stress induction and caspase-3 processing suggesting that Reolysin and gemcitabine treatment exhibited direct pro-apoptotic activity against the tumor.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-015-1518-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.4244118", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438859", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer", 
    "pagination": "513", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "571d12468eaf1be04b5e46a4dc0f6981cf55382f6e531ba6a2c4c7228497ebf2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26156229"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-015-1518-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018283520"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-015-1518-0", 
      "https://app.dimensions.ai/details/publication/pub.1018283520"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89793_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fs12885-015-1518-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1518-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1518-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1518-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1518-0'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      58 URIs      31 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-015-1518-0 schema:about N013dd8f0d3cb4e27aff1e72a0c124a5f
2 N306302ec35ee43a08d1c2fd65f3dce87
3 N3b7ee7f38d294e7c936b4c5306af565a
4 N44924632bc994563b9861a1e5fff465c
5 N5e37722d90ae4b2194dd07fdde1d6a7a
6 N621f7bd8514d454dac89c03cbad33fc4
7 N95d448163f2847a78b920173f7f0addc
8 Na007ed59f5e74edfb6af3a37b2573d71
9 Nac36a5c5a51e46f9959171bd60b161a0
10 Nefdd1e1240b34afa872937ceaea13b16
11 anzsrc-for:11
12 anzsrc-for:1112
13 schema:author Nf8ecd7594c7d430b8ff9679ff697c939
14 schema:citation sg:pub.10.1007/s10637-012-9865-z
15 sg:pub.10.1007/s10637-015-0216-8
16 sg:pub.10.1038/cddis.2013.259
17 sg:pub.10.1038/modpathol.2012.95
18 sg:pub.10.1038/onc.2011.478
19 sg:pub.10.1186/1471-2407-12-368
20 https://app.dimensions.ai/details/publication/pub.1075250670
21 https://doi.org/10.1002/ijc.27918
22 https://doi.org/10.1016/0092-8674(88)90571-5
23 https://doi.org/10.1016/j.ejca.2008.10.026
24 https://doi.org/10.1093/emboj/17.12.3351
25 https://doi.org/10.1126/science.282.5392.1332
26 https://doi.org/10.1158/1078-0432.ccr-10-1233
27 https://doi.org/10.1158/1078-0432.ccr-10-2159
28 https://doi.org/10.1158/1078-0432.ccr-11-2181
29 https://doi.org/10.1158/1541-7786.mcr-12-0157
30 https://doi.org/10.1200/jco.1997.15.6.2403
31 https://doi.org/10.1200/jco.2011.34.8904
32 https://doi.org/10.1517/14712590903002039
33 schema:datePublished 2015-12
34 schema:datePublishedReg 2015-12-01
35 schema:description BACKGROUND: Activating mutations in RAS are present in the majority of pancreatic cancer cases and represent an ideal therapeutic target. Reolysin is a proprietary formulation of oncolytic reovirus that is currently being evaluated in multiple clinical trials due to its ability to selectively replicate in cells harboring an activated RAS pathway. Here we report for the first time the presence of reovirus replication and induction of endoplasmic reticular (ER) stress in a primary tumor specimen collected from a pancreatic cancer patient receiving intravenous Reolysin and gemcitabine. CASE PRESENTATION: We describe the case of a 54-year old patient diagnosed with pancreatic adenocarcinoma in February 2012. Analysis of a tumor biopsy revealed an activating KRAS mutation (G12D) and the patient was started on first-line treatment with Reolysin in combination with gemcitabine in March 2012. Stable disease was achieved with significant improvement in cancer-related pain. Following 25 cycles of treatment over 23 months, a second biopsy was collected and immunohistochemical analyses revealed the presence of reovirus replication and induction of the ER stress-related gene GRP78/BIP and the pro-apoptotic protein NOXA. Importantly, co-localization of reoviral protein and active caspase-3 was also observed in the biopsy specimen. CONCLUSION: This is the first report of reoviral protein detection in primary tumor biopsies taken from a pancreatic cancer patient receiving intravenous Reolysin therapy. The accumulation of reoviral protein was associated with ER stress induction and caspase-3 processing suggesting that Reolysin and gemcitabine treatment exhibited direct pro-apoptotic activity against the tumor.
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree true
39 schema:isPartOf N74f2de8169ee45ed9fa166b1b532148d
40 Ndda3ec28085c47888ad476ce58320f39
41 sg:journal.1024632
42 schema:name The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
43 schema:pagination 513
44 schema:productId N1b1f41323ac144d1b3eb28fb92ef32da
45 N2076dd4956b349e1be273baf8af018f4
46 N7b25ccbcaf9143ec860e8228d4f2036a
47 Nc55e8ac05fbb444d8a57120a4277578a
48 Ne3fdaebdc7cd458698dadf5911cfa0a5
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018283520
50 https://doi.org/10.1186/s12885-015-1518-0
51 schema:sdDatePublished 2019-04-11T09:53
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N9aa0e68cfcd6401a801e1546c4909cc4
54 schema:url http://link.springer.com/10.1186%2Fs12885-015-1518-0
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N013dd8f0d3cb4e27aff1e72a0c124a5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Middle Aged
60 rdf:type schema:DefinedTerm
61 N12a74c44be3a44a09deb0c5d58c98684 schema:name Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA
62 rdf:type schema:Organization
63 N1b1f41323ac144d1b3eb28fb92ef32da schema:name dimensions_id
64 schema:value pub.1018283520
65 rdf:type schema:PropertyValue
66 N2076dd4956b349e1be273baf8af018f4 schema:name pubmed_id
67 schema:value 26156229
68 rdf:type schema:PropertyValue
69 N2a5ed2d43690419bb0d1f610f44375e0 rdf:first sg:person.0770375641.19
70 rdf:rest N8c1269a082cd4b5a8e16467d88d53665
71 N2b4245b00e4c416283995634a4022e48 rdf:first sg:person.01024605131.74
72 rdf:rest N82ce885493a6479c96039016b4159cb9
73 N306302ec35ee43a08d1c2fd65f3dce87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Proto-Oncogene Proteins p21(ras)
75 rdf:type schema:DefinedTerm
76 N3b7ee7f38d294e7c936b4c5306af565a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Reoviridae
78 rdf:type schema:DefinedTerm
79 N44924632bc994563b9861a1e5fff465c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Humans
81 rdf:type schema:DefinedTerm
82 N5e37722d90ae4b2194dd07fdde1d6a7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Pancreas
84 rdf:type schema:DefinedTerm
85 N621f7bd8514d454dac89c03cbad33fc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Endoplasmic Reticulum Stress
87 rdf:type schema:DefinedTerm
88 N74f2de8169ee45ed9fa166b1b532148d schema:volumeNumber 15
89 rdf:type schema:PublicationVolume
90 N7b25ccbcaf9143ec860e8228d4f2036a schema:name readcube_id
91 schema:value 571d12468eaf1be04b5e46a4dc0f6981cf55382f6e531ba6a2c4c7228497ebf2
92 rdf:type schema:PropertyValue
93 N82ce885493a6479c96039016b4159cb9 rdf:first sg:person.01205716075.13
94 rdf:rest N2a5ed2d43690419bb0d1f610f44375e0
95 N838347e744d84bcd81ad8a120070ac57 rdf:first sg:person.01130425414.81
96 rdf:rest rdf:nil
97 N8c1269a082cd4b5a8e16467d88d53665 rdf:first sg:person.01014326765.89
98 rdf:rest N838347e744d84bcd81ad8a120070ac57
99 N95d448163f2847a78b920173f7f0addc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Male
101 rdf:type schema:DefinedTerm
102 N9aa0e68cfcd6401a801e1546c4909cc4 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 Na007ed59f5e74edfb6af3a37b2573d71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Pancreatic Neoplasms
106 rdf:type schema:DefinedTerm
107 Naa4628b08e1047728f76f6de0fc51cb5 schema:name Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA
108 rdf:type schema:Organization
109 Nac36a5c5a51e46f9959171bd60b161a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Deoxycytidine
111 rdf:type schema:DefinedTerm
112 Nade9bcc93166459fb6a15926a3df8a8a rdf:first sg:person.0714313216.40
113 rdf:rest N2b4245b00e4c416283995634a4022e48
114 Nc55e8ac05fbb444d8a57120a4277578a schema:name nlm_unique_id
115 schema:value 100967800
116 rdf:type schema:PropertyValue
117 Nc9440a0dd14b4b7a85c90f9c991a7fb4 schema:name Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, 78229, San Antonio, TX, USA
118 rdf:type schema:Organization
119 Ndda3ec28085c47888ad476ce58320f39 schema:issueNumber 1
120 rdf:type schema:PublicationIssue
121 Ne3fdaebdc7cd458698dadf5911cfa0a5 schema:name doi
122 schema:value 10.1186/s12885-015-1518-0
123 rdf:type schema:PropertyValue
124 Nefdd1e1240b34afa872937ceaea13b16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Antineoplastic Agents
126 rdf:type schema:DefinedTerm
127 Nf8ecd7594c7d430b8ff9679ff697c939 rdf:first sg:person.01355241314.34
128 rdf:rest Nade9bcc93166459fb6a15926a3df8a8a
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
133 schema:name Oncology and Carcinogenesis
134 rdf:type schema:DefinedTerm
135 sg:grant.2438859 http://pending.schema.org/fundedItem sg:pub.10.1186/s12885-015-1518-0
136 rdf:type schema:MonetaryGrant
137 sg:grant.4244118 http://pending.schema.org/fundedItem sg:pub.10.1186/s12885-015-1518-0
138 rdf:type schema:MonetaryGrant
139 sg:journal.1024632 schema:issn 1471-2407
140 schema:name BMC Cancer
141 rdf:type schema:Periodical
142 sg:person.01014326765.89 schema:affiliation https://www.grid.ac/institutes/grid.459870.7
143 schema:familyName Coffey
144 schema:givenName Matt
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014326765.89
146 rdf:type schema:Person
147 sg:person.01024605131.74 schema:affiliation https://www.grid.ac/institutes/grid.261331.4
148 schema:familyName Nuovo
149 schema:givenName Gerard
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024605131.74
151 rdf:type schema:Person
152 sg:person.01130425414.81 schema:affiliation N12a74c44be3a44a09deb0c5d58c98684
153 schema:familyName Nawrocki
154 schema:givenName Steffan T.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130425414.81
156 rdf:type schema:Person
157 sg:person.01205716075.13 schema:affiliation https://www.grid.ac/institutes/grid.459870.7
158 schema:familyName Gill
159 schema:givenName George
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205716075.13
161 rdf:type schema:Person
162 sg:person.01355241314.34 schema:affiliation Nc9440a0dd14b4b7a85c90f9c991a7fb4
163 schema:familyName Mahalingam
164 schema:givenName Devalingam
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355241314.34
166 rdf:type schema:Person
167 sg:person.0714313216.40 schema:affiliation Naa4628b08e1047728f76f6de0fc51cb5
168 schema:familyName Patel
169 schema:givenName Sukeshi
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714313216.40
171 rdf:type schema:Person
172 sg:person.0770375641.19 schema:affiliation https://www.grid.ac/institutes/grid.459870.7
173 schema:familyName Selvaggi
174 schema:givenName Giovanni
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770375641.19
176 rdf:type schema:Person
177 sg:pub.10.1007/s10637-012-9865-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1010325857
178 https://doi.org/10.1007/s10637-012-9865-z
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/s10637-015-0216-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015566041
181 https://doi.org/10.1007/s10637-015-0216-8
182 rdf:type schema:CreativeWork
183 sg:pub.10.1038/cddis.2013.259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032595002
184 https://doi.org/10.1038/cddis.2013.259
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/modpathol.2012.95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051526491
187 https://doi.org/10.1038/modpathol.2012.95
188 rdf:type schema:CreativeWork
189 sg:pub.10.1038/onc.2011.478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010906274
190 https://doi.org/10.1038/onc.2011.478
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/1471-2407-12-368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037287741
193 https://doi.org/10.1186/1471-2407-12-368
194 rdf:type schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1075250670 schema:CreativeWork
196 https://doi.org/10.1002/ijc.27918 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047508013
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/0092-8674(88)90571-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052805579
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1093/emboj/17.12.3351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025374400
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1126/science.282.5392.1332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062563200
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1158/1078-0432.ccr-10-1233 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031485445
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1158/1078-0432.ccr-10-2159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032446761
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1158/1078-0432.ccr-11-2181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021662085
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1158/1541-7786.mcr-12-0157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036233281
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1200/jco.1997.15.6.2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083106816
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1200/jco.2011.34.8904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049252722
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1517/14712590903002039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067587980
219 rdf:type schema:CreativeWork
220 https://www.grid.ac/institutes/grid.261331.4 schema:alternateName The Ohio State University
221 schema:name Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
222 rdf:type schema:Organization
223 https://www.grid.ac/institutes/grid.459870.7 schema:alternateName Oncolytics Biotech (Canada)
224 schema:name Oncolytics Biotech, Inc., Calgary, AB, Canada
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...